Retatrutide Nears FDA Filing After 28% Weight Loss in Phase 3

Retatrutide nears an FDA filing after a strong run of trial results

Eli Lilly's experimental obesity drug retatrutide has spent 2026 producing some of the largest weight-loss figures reported in a late-stage drug trial. Its main obesity study, TRIUMPH-1, read out in May. Participants on the highest 12 mg dose lost an average of 28.3% of their body weight, about 70.3 pounds, over 80 weeks, and 45.3% of them lost at least 30%.21 In a pre-specified blinded extension for participants with a baseline BMI of 35 or higher, those who stayed on 12 mg through 104 weeks lost an average of 30.3%, or 85 pounds.21 That extension result is the source of the "30% of body weight" figure in many headlines. It applies to a subgroup over two years, not to everyone in the trial.

Retatrutide is described as a first-in-class "triple agonist." It acts on three hormone receptors: GLP-1, GIP and glucagon.21 Semaglutide (Wegovy) targets only GLP-1, and tirzepatide (Zepbound) targets GLP-1 and GIP.28 Lilly argues that the glucagon component adds weight loss on top of the appetite suppression the older drugs already provide.

The headline numbers matter commercially, but the regulatory timeline matters more. Lilly now says it will submit retatrutide to the FDA in the first quarter of 2027. Earlier this year it had included the drug among products that might be filed by the end of 2026.4

Several trials, consistent results

TRIUMPH-1 is one of several Phase 3 readouts. The first came in December 2025 from TRIUMPH-4, a trial in people with obesity and knee osteoarthritis. The 12 mg dose produced an average weight loss of 28.7% at 68 weeks, compared with 2.1% on placebo.30 In March 2026, TRANSCEND-T2D-1 tested the drug as a type 2 diabetes treatment. It cut A1C by up to 2.0% and reduced weight by up to 16.8% at 40 weeks, with no plateau in weight loss by the end of the treatment period.29

TRIUMPH-2 and TRIUMPH-3 reported in July. TRIUMPH-2 enrolled people with obesity and type 2 diabetes and showed 20.8% weight loss on the top dose. TRIUMPH-3 enrolled people with obesity and established cardiovascular disease and showed 22.6%.1 Full TRIUMPH-2 results were published in The Lancet on September 29 and presented at the EASD meeting in Milan. On the 12 mg dose, 59.5% of participants no longer met the BMI threshold for obesity, and A1C fell by about 1.5 to 1.6 points at the higher doses.22

The trial results point the same way. Weight loss is clearly lower in people with diabetes, which matches the pattern seen with earlier GLP-1 drugs. Still, every trial reported clinically meaningful reductions at every dose tested. The lowest dose may turn out to be one of the more important findings. With a single dose-escalation step, 4 mg produced 19.0% weight loss at 80 weeks, and fewer people stopped treatment because of side effects on that dose than on placebo.21 My reading is that Lilly is building a case for a range of doses rather than just one high-dose drug. The company has described retatrutide, alongside Zepbound and its pill Foundayo, as a way to match treatment to patient needs.21

Comparing it with older drugs is harder than headlines suggest

Much of the coverage puts retatrutide's roughly 28% next to tirzepatide's roughly 22.5% in SURMOUNT-1 and semaglutide's roughly 15% in STEP-1, and calls retatrutide the clear leader.3027 These comparisons are useful as rough guides but do not settle the question. No completed trial has yet compared retatrutide directly with another GLP-1 medicine.28 Trial populations, durations and baseline weights also differ. TRIUMPH-1 participants started at an average BMI of 40,21 which is heavier than in some earlier studies.

The direct comparison is coming. TRIUMPH-5, which pits retatrutide against tirzepatide, is expected to finish around December 2026.2 That result is likely to shape how doctors, insurers and investors value the drug, because Lilly will be competing against its own best-selling product. A clear win would show retatrutide's advantage is real. A narrow margin would push the conversation toward tolerability, dosing flexibility and price.

Coverage also differs on how much the data has been independently checked. One healthcare provider's explainer noted in September that the headline Phase 3 numbers came from company press releases rather than peer-reviewed papers.6 That point is now partly outdated. TRIUMPH-2 has appeared in The Lancet,22 and the Phase 2 obesity results were published in the New England Journal of Medicine in 2023.1 The full peer-reviewed TRIUMPH-1 paper, including detailed safety tables, is still the most important piece of evidence to watch for.

Why the filing slipped to 2027

The delay is about paperwork and manufacturing, not clinical results. Lilly told CNBC it needed more time to compile manufacturing and quality-control data for the FDA.4 Another tracker described the gap as the chemistry, manufacturing and controls package, and noted that Lilly repeated the first-quarter 2027 target on September 29.2

Coverage varies on what kind of application Lilly will file. Some consumer guides still refer to a New Drug Application (NDA).527 Reporting based on Lilly's July announcement describes a Biologics License Application (BLA).16 The difference goes beyond paperwork, because it affects which regulatory track the drug follows.

Estimates of when the FDA could decide fall in a fairly narrow range. A standard review would put a decision around early 2028. Priority review would bring it to roughly the third or fourth quarter of 2027.2 Drugs.com also points to late 2027 or 2028 and notes that no approval or launch date has been confirmed.3

Recent approvals show the range of possible speeds. Foundayo went from FDA receipt in January 2026 to approval on April 1, a 71-day review that used a National Priority Voucher.1 No such voucher has been announced for retatrutide.2 The more likely outcome is a decision around the turn of 2028. It could come sooner if the FDA grants retatrutide the kind of fast-track treatment it gave Foundayo.

In the meantime, Lilly has opened a narrow route to the drug. In August it confirmed a limited expanded-access program for patients who meet specific medical criteria and cannot join a trial.102 That matters because of a growing grey market. Regulators and clinicians warn that anything sold online as "retatrutide" is not an approved product. A death in the UK has been linked to a product sold as retatrutide, although it is unclear whether the drug caused the death or whether the product came from the black market.283

The sales picture: Lilly is defending its lead

Retatrutide arrives with Lilly already ahead in the obesity market. Second-quarter revenue rose 48% to almost $23 billion, beating analyst consensus of $20.6 billion, with tirzepatide described as the world's best-selling drug.12 Mounjaro brought in about $9.9 billion in the quarter and U.S. Zepbound about $4.9 billion.20 Full-year guidance now stands at $85 to $87 billion.16 Earlier in the year, Lilly said it held just over 60% of the U.S. market for these drugs, compared with 39.4% for Novo Nordisk.14

The oral-drug market looks less settled. Novo's Wegovy pill had a fast start, with first-quarter sales of about $354 million, almost double analyst estimates.11 Second-quarter sales of about $494 million fell slightly short of forecasts.12 Lilly's Foundayo, approved April 1, made $98 million in the second quarter against a $104 million consensus.1214 Novo's CEO also said in May that the Wegovy brand held 65% of new U.S. prescriptions.13 Lilly's share of total sales and Novo's share of new prescriptions measure different things, which helps explain why both companies can claim to be winning.

The longer-term contest is over next-generation drugs, and here Lilly is clearly ahead. Novo's CagriSema combination fell short of Zepbound in a weight-loss study and later of tirzepatide on blood-sugar control in type 2 diabetes.1213 Novo's own triple-acting candidate is reportedly further behind.11 Investors have taken note. JPMorgan recently raised its Lilly price target to $1,500, citing the TRIUMPH-2 data and the planned 2027 filing.16

Price is one factor that may limit how much any new drug can earn. Wegovy and Zepbound launched at around $1,000 a month and now sell through company websites for starting prices of $149 to $299, partly because of a deal with the Trump administration.17 Reuters reported that the most optimistic market forecasts are looking less secure as prices fall.17 Analysts cited by CNBC still expect the weight-loss market to reach $100 billion by the end of the decade.13

What it means

In my reading, retatrutide is the most important pipeline asset in the obesity field, and its efficacy is no longer seriously in doubt. The open questions are about how the drug will be used and paid for. Will insurers cover a drug that produces close to surgical-level weight loss, at prices that keep falling? Will doctors save the 12 mg dose for severe obesity and start most patients on 4 mg? Will TRIUMPH-5 show a clear enough advantage over Zepbound to justify switching patients? The first answers should come in roughly three months, when the head-to-head data arrives. The FDA filing would follow shortly after.